GlobeNewswire Inc.Mar 17, 10:59 AM ET▼ Negative
Subject to class action investigation regarding merger with Candid Therapeutics, with concerns potentially related to the 3.65% ownership stake in the combined entity.
Rallybio news
$17.05+2.59%
Close Sep 28, 2026 · split-adjustedArticles · 30 days0English, de-duplicated
Positive0
Neutral0
Negative0
About Rallybio
BenzingaMar 2, 10:51 AM ET▲ Positive
Stock surged 29.05% to a new 52-week high following the announcement of a merger with well-funded Candid Therapeutics. The combined entity will have strong financial backing ($700 million pro-forma cash) to advance multiple clinical programs through 2030, demonstrating investor confidence in the merger's strategic value.
Also mentions RLYB
Articles that tag RLYB but are mainly about other companies.
None recently.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology